Steffen Goerke1, Johannes Breitling1, Andreas Korzowski1, Daniel Paech2, Moritz Zaiss3,4, Heinz-Peter Schlemmer2,5, Mark E Ladd1,5,6, Peter Bachert1,6. 1. Department of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2. Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. Department of Neuroradiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. 4. High-field Magnetic Resonance Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany. 5. Faculty of Medicine, University of Heidelberg, Heidelberg, Germany. 6. Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany.
Abstract
PURPOSE: The value of relaxation-compensated amide proton transfer (APT) and relayed nuclear Overhauser effect (rNOE) chemical exchange saturation transfer (CEST)-MRI has already been demonstrated in various neuro-oncological clinical applications. Recently, we translated the approach from 7T to a clinically relevant magnetic field strength of 3T. However, the overall acquisition time was still too long for a broad application in the clinical setting. The aim of this study was to establish a shorter acquisition protocol whilst maintaining the contrast behavior and reproducibility. METHODS: Ten patients with glioblastoma were examined using the previous state-of-the-art acquisition protocol at 3T. The acquired spectral data were retrospectively reduced to find the minimal amount of required information that allows obtaining the same contrast behavior. To further reduce the acquisition time, also the image readout was accelerated and the pre-saturation parameters were further optimized. RESULTS: In total, the overall acquisition time could be reduced from 19 min to under 7 min. One key finding was that, when evaluated by the relaxation-compensated inverse metric, a contrast correction for B1 -field inhomogeneities at 3T can also be achieved reliably with CEST data at only one B1 value. In contrast, a 1-point B1 -correction was not sufficient for the common linear difference evaluation. The reproducibility of the new clinical routine acquisition protocol was similar to the previous state-of-the-art protocol with limits of agreement below 20%. CONCLUSIONS: The substantial reduction in acquisition time by about 64% now allows the application of 3D relaxation-compensated APT and rNOE CEST-MRI for examinations of the human brain at 3T in clinical routine.
PURPOSE: The value of relaxation-compensated amide proton transfer (APT) and relayed nuclear Overhauser effect (rNOE) chemical exchange saturation transfer (CEST)-MRI has already been demonstrated in various neuro-oncological clinical applications. Recently, we translated the approach from 7T to a clinically relevant magnetic field strength of 3T. However, the overall acquisition time was still too long for a broad application in the clinical setting. The aim of this study was to establish a shorter acquisition protocol whilst maintaining the contrast behavior and reproducibility. METHODS: Ten patients with glioblastoma were examined using the previous state-of-the-art acquisition protocol at 3T. The acquired spectral data were retrospectively reduced to find the minimal amount of required information that allows obtaining the same contrast behavior. To further reduce the acquisition time, also the image readout was accelerated and the pre-saturation parameters were further optimized. RESULTS: In total, the overall acquisition time could be reduced from 19 min to under 7 min. One key finding was that, when evaluated by the relaxation-compensated inverse metric, a contrast correction for B1 -field inhomogeneities at 3T can also be achieved reliably with CEST data at only one B1 value. In contrast, a 1-point B1 -correction was not sufficient for the common linear difference evaluation. The reproducibility of the new clinical routine acquisition protocol was similar to the previous state-of-the-art protocol with limits of agreement below 20%. CONCLUSIONS: The substantial reduction in acquisition time by about 64% now allows the application of 3D relaxation-compensated APT and rNOE CEST-MRI for examinations of the human brain at 3T in clinical routine.
Authors: Lee Sze Foo; George Harston; Amit Mehndiratta; Wun-She Yap; Yan Chai Hum; Khin Wee Lai; Shahizon Azura Mohamed Mukari; Faizah Mohd Zaki; Yee Kai Tee Journal: Quant Imaging Med Surg Date: 2021-08
Authors: Julia P Lingl; Arthur Wunderlich; Steffen Goerke; Daniel Paech; Mark E Ladd; Patrick Liebig; Andrej Pala; Soung Yung Kim; Michael Braun; Bernd L Schmitz; Meinrad Beer; Johannes Rosskopf Journal: Diagnostics (Basel) Date: 2022-02-14
Authors: Yulun Wu; Tobias C Wood; Fatemeh Arzanforoosh; Juan A Hernandez-Tamames; Gareth J Barker; Marion Smits; Esther A H Warnert Journal: MAGMA Date: 2022-01-07 Impact factor: 2.310
Authors: Jinyuan Zhou; Moritz Zaiss; Linda Knutsson; Phillip Zhe Sun; Sung Soo Ahn; Silvio Aime; Peter Bachert; Jaishri O Blakeley; Kejia Cai; Michael A Chappell; Min Chen; Daniel F Gochberg; Steffen Goerke; Hye-Young Heo; Shanshan Jiang; Tao Jin; Seong-Gi Kim; John Laterra; Daniel Paech; Mark D Pagel; Ji Eun Park; Ravinder Reddy; Akihiko Sakata; Sabine Sartoretti-Schefer; A Dean Sherry; Seth A Smith; Greg J Stanisz; Pia C Sundgren; Osamu Togao; Moriel Vandsburger; Zhibo Wen; Yin Wu; Yi Zhang; Wenzhen Zhu; Zhongliang Zu; Peter C M van Zijl Journal: Magn Reson Med Date: 2022-04-22 Impact factor: 3.737